

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ATADJA ET AL.

APPLICATION NO: 10/567,897

FILED: SEPTEMBER 22, 2006

FOR: COMBINATIONS COMPRISING STAUROSPORINES

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office action dated January 2, 2008, response due within one month on Monday, February 4, 2008, kindly enter the following response.

In response to the restriction requirement under 35 USC 121, Applicants elect the claims of Group I, claims 1-14 and 15-20.

In response to the requirement to elect single species for initial examination, Applicants elect the following:

FLT-3 inhibitor – Midostaurin described as Compound of formula VII on page 31 of the PCT publication of this application, WO2005/014004.

HDAI – *N*-hydroxy-3-[4-[[[2-(2-methyl-1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide of the formula



Disease species – acute myeloid leukemia (AML)

Of the elected claims, claims 1-20 read on the combination of the three elected species.

Entry of this response is requested and an action on the merits is awaited.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis
Corporate Intellectual Property
One Health Plaza
East Hanover, NJ 07936-1080
(862) 778-7824

Date: January 31, 2008